前收市價 | 43.49 |
開市 | 43.73 |
買盤 | 43.97 x 300 |
賣出價 | 44.07 x 300 |
今日波幅 | 43.28 - 44.31 |
52 週波幅 | 15.76 - 49.58 |
成交量 | |
平均成交量 | 817,714 |
市值 | 3.43B |
Beta 值 (5 年,每月) | 0.62 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -3.69 |
業績公佈日 | 2024年5月02日 - 2024年5月06日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 57.92 |
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tuesday, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) released topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of paltusotine for acromegaly. Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. The 111-participant study met statistical significance (p<0.0001) on the primary endpoint, based on the proportion of participants taking paltusotine (56%) who achieved an insulin-l